Introduction
Standard ART contains three drugs, 1, 2 but reducing the number of antiretrovirals to simplify therapy and to avoid the negative impact of drug exposure is an attractive strategy. Boosted PI maintenance monotherapy has a risk of viral rebound higher than that with standard triple therapy but fortunately no major resistance emergence has been reported so far. 3 In contrast to monotherapy, dual therapy with boosted PIs plus lamivudine has shown noninferiority compared with standard triple therapy in antiretroviralexperienced HIV-infected patients. 4 PI dual therapy or monotherapy may nevertheless cause digestive, metabolic and other PI-related adverse effects, and bring the risk of clinically significant interactions due to PI boosters. 5 Dolutegravir shares several favourable characteristics with boosted PIs, including high potency, high inhibitory quotient and high barrier to resistance, that make it appealing for antiretroviral regimens with fewer than three drugs. Furthermore, dolutegravir also demonstrates a lack of interference with comorbidities, a low risk for interactions, a longer half-life and is easier to take and better tolerated than boosted PIs. 6 Lamivudine, the most commonly used antiretroviral drug to date, is still considered in major guidelines, has shown no major related toxicities, has a low likelihood of drug-drug interactions, and promising data have emerged from PI-based dual-therapy maintenance studies. 1, 2, 4 A preliminary review of 33 HIV-infected patients from Hospital Clínic (Barcelona, Spain) who had their ART switched to dolutegravir monotherapy on an individual clinical basis showed 97% efficacy at 24 weeks; 7 although one patient developed viral failure, this patient had a psychiatric comorbidity with suboptimal adherence to ART. Clinical experience of dual therapy with dolutegravir/ lamivudine in antiretroviral-experienced patients has been also promising. 8, 9 Based on these data, we hypothesized that dolutegravir/lamivudine dual therapy or dolutegravir monotherapy would have efficacy similar to that of triple ART in patients with sustained viral suppression.
Methods

Study design
The DOLAM Study is a multicentre, randomized, controlled with active treatment, open-label, parallel clinical trial comprising two phases, A and B. Phase A aimed to include 30 patients per arm and follow them for at least 24 weeks. This phase was performed for futility purposes to assess whether experimental arms were subjected to an unacceptable (defined as 5%) rate of viral failure. Phase B was intended to include the full number of patients and follow them for 48 weeks. Figure 1 shows the design of the DOLAM Study.
In phase A, eligible participants were randomly assigned in a 1:1:1 ratio to one of the following arms: to continue current treatment (control arm), to switch to dolutegravir (50 mg)/lamivudine (300 mg) once daily (dualtherapy arm), or to switch to 50 mg of dolutegravir once daily (monotherapy arm) (Figure 1) . A random sequence was generated by a computer stratifying by anchor drug (PI, NNRTI or integrase inhibitor). The assignment was centralized and communicated by telephone.
Premature discontinuation was considered if there was viral failure (defined as two consecutive plasma HIV RNA measurements 50 copies/mL or a single HIV-1 RNA value .1000 copies/mL) or therapy interruption due to adverse events, concurrent illness, protocol deviation or patient's wish. Blips were registered. The study is currently ongoing and the planned phase A results at 24 weeks are reported here. The Data Safety Monitoring Board (DSMB) reviews the data if the proportion of confirmed viral failures in any of the experimental arms reaches 5%.
Ethics
Institutional review boards from participating centres approved the study and written informed consent was obtained from all eligible patients before randomization. The study is registered at EudraCT, number: 201500027435.
Patients
Consecutive clinically stable HIV-infected adults (18 years old) on stable (defined as at least the previous 12 months) triple ART based on PIs, NNRTIs or integrase inhibitors with sustained viral suppression (defined by plasma HIV RNA ,50 copies/mL in two or more consecutive determinations during at least the 12 months prior to inclusion; blips up to 200 copies/mL were permitted) were invited to participate (Figure 1 ). For women of childbearing age, a negative pregnancy test within 10 days prior to randomization into the study was required. Exclusion criteria were: pregnancy, lactation or planned pregnancy during the study period; prior virological failure (defined as plasma HIV RNA 50 copies/mL in two consecutive tests or .500 copies/mL in one test) to regimens containing lamivudine/emtricitabine or integrase inhibitors; any mutation conferring resistance to lamivudine/emtricitabine or integrase inhibitors if genotypic testing had been previously performed; nadir CD4 ,200 cells/mm 3 ; any disease or history of disease that, in the opinion of the investigator, might confound the results of the study or pose additional risk to patient treatment; and chronic hepatitis B (defined by positivity for hepatitis B surface antigen).
Outcomes
The major endpoint of the DOLAM Study is to determine therapeutic efficacy and viral failure rate (FDA snapshot algorithm) assessed with standard plasma HIV-1 RNA detection (defined by a limit of detection of 50 copies/mL) at 48 weeks. For the purpose of the phase A analysis reported here, we described rates of viral failure and blips, and adverse events at 24 weeks among the three arms.
In the event of viral failure, plasma and PBMCs were tested for HIV reverse transcriptase, protease and integrase resistance mutations by population sequencing (Trugene, Siemens) and ultra-deep sequencing (MiSeq platform, Illumina), respectively, following routine protocols.
At each visit, whole blood samples were collected in test tubes containing heparin sodium 24 h after administration of dolutegravir. The blood samples were centrifuged at 1200 g for 10 min to isolate 2 mL of plasma Blanco et al.
and 3-4 aliquots with 5 mL of pellet, which were stored at #80 C until assayed. In patients developing viral failure, dolutegravir, raltegravir and elvitegravir plasma concentrations were measured in samples available using mass spectrometry at a mass-to-charge ratio of 420 using the MassLynx analysis software version 4.0 (Waters Corp., Milford, MA). Raltegravir and elvitegravir plasma concentrations were measured to rule out potential exposure to these integrase inhibitors influencing the development of resistance mutations. Dolutegravir plasma concentrations were compared with the in vitro, protein-adjusted 90% inhibitory concentration (IC 90 ) of dolutegravir for WT virus (64 ng/mL). 10 
Procedures
All patients were visited at baseline, 12 and 24 weeks. At baseline, patients' characteristics, including age, gender, suspected route of HIV transmission and anchor drug, were collected. At each visit, participants had a complete physical examination done and blood drawn for CD4 and CD8 cell counts and standard plasma HIV-1 RNA (limit of detection 20 copies/mL at Hospital Clínic, and 40 copies/mL at Hospital Universitari Germans Trias i Pujol, but homogenized for the purpose of this study to ,50 copies/mL to define plasma viral suppression). Patients allocated to the experimental arms had also blood drawn for standard plasma HIV-1 RNA at 4 weeks to detect potential early viral failure. At each follow-up visit, information on adverse events and use of drugs other than ART was collected, a simplified adherence questionnaire was administered, 11 and a pregnancy test for women of childbearing age was performed. Intensity of adverse events was assessed according to the Division of AIDS table for grading the severity of adult and paediatric adverse events. 12 
Results
Baseline characteristics
There were 91 patients included in the phase A of the DOLAM Study: 31 patients in the control arm, 29 patients in the dual-therapy arm and 31 patients in the monotherapy arm. Table 1 shows the characteristics of the patients. Most patients were middleaged adult men who had sex with men. The mean absolute CD4 cell concentration was 739 cells/mm 3 , and the mean CD4/CD8 ratio was nearly 1. The anchor drug was most commonly an NNRTI (70%) followed by an integrase inhibitor (17%) and a PI (13%), reflecting the use of these drugs in the population to whom the study was addressed.
Patients' disposition at 24 weeks
Three patients prematurely discontinued due to viral failure. None of them had been previously exposed to integrase inhibitor therapy. One of these patients (subject A) had been assigned to dual therapy and viral failure occurred at week 12. The other two patients (subjects B and C) had been assigned to monotherapy and viral failure occurred at week 24 in both cases. No patient assigned to the control arm experienced viral failure. There were no discontinuations for other reasons. Only one patient (assigned to dual therapy) experienced a blip at week 4.
Viral failures
The patient assigned to dual therapy who developed viral failure (subject A) (Figure 2a switched to darunavir plus ritonavir in 2012 due to sleep problems potentially associated with efavirenz. The patient, who had been virally suppressed for 8 years, experienced viral rebound due to lack of adherence to the new regimen because of gastrointestinal adverse effects. The patient was switched again to the previous regimen, regaining viral suppression for 122 weeks until entering the DOLAM Study and was randomized to dual therapy. The plasma dolutegravir concentration at week 4 was 1776 ng/mL, well above the in vitro, protein-adjusted IC 90 of dolutegravir for WT virus. At 12 weeks, viral load showed a low-level rebound and viral failure was confirmed. No resistance mutations were detected in plasma and some low-abundance variants to NRTIs and NNRTIs were detected in PBMCs. The patient switched to dolutegravir/lamivudine/abacavir, regaining viral suppression in plasma.
One of the two patients assigned to monotherapy who developed viral failure (subject B) (Figure 2b ) had been virally suppressed with efavirenz/emtricitabine/tenofovir disoproxil fumarate for at least 9 years before participating in the DOLAM Study. The patient remained virally suppressed until week 24 when the patient experienced viral rebound to 96 copies/mL, later confirmed as 1266 copies/mL. Plasma dolutegravir levels before and at the moment of viral failure largely exceeded those of the in vitro, protein-adjusted IC 90 of dolutegravir for WT virus. De novo integrase mutations S147G and N155H were detected in plasma at the time of virological failure and virological failure confirmation, and low-abundance Q148R mutation (3%) also appeared at the time of virological failure confirmation. The patient switched to emtricitabine/tenofovir disoproxil fumarate plus rilpivirine, and later from rilpivirine to darunavir/cobicistat, regaining viral suppression in plasma.
The other patient assigned to monotherapy who developed viral failure (subject C) (Figure 2c ) had been diagnosed with HIV-1 infection in 2008. The patient began therapy with efavirenz, emtricitabine and tenofovir disoproxil fumarate in 2012. The patient remained virally suppressed for .3 years until the patient was recruited for the DOLAM Study. The patient remained virally suppressed until week 24 when the patient's plasma viral load was Two dolutegravir-based less-drug maintenance regimens JAC 50 copies/mL. The patient did not attend for confirmation of viral failure until 10 weeks later. At that time, the plasma viral load was 106 copies/mL and 2 weeks later it was 426 copies/mL. De novo integrase mutations E138K and N155H were detected in plasma at both timepoints, and low-abundance G140S mutation (4%) also appeared in the first genotypic resistance analysis. Dolutegravir plasma levels were not measured in this patient, but self-reported and pharmacy-measured adherence was excellent. The patient switched to darunavir/cobicistat monotherapy, regaining viral suppression in plasma. Table 2 shows the profile and intensity of adverse events in the three study arms. Patients assigned to both dual-therapy and monotherapy arms experienced more adverse effects than patients assigned to the control arm, but most adverse effects were Grade 1. Infections and neuropsychiatric effects were more common in both experimental arms compared with the control arm. No patient discontinued therapy due to adverse effects. . EFV, efavirenz; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate; DTG, dolutegravir; 3TC, lamivudine; ABC, abacavir; ELV, elvitegravir; NVP, nevirapine; COBI, cobicistat; RPV, rilpivirine; DRM, drug resistance mutation; LLQ, lower limit of quantification.
Adverse events
DSMB report
As pre-planned in the protocol, the DSMB was convened to review the data because the proportion of confirmed viral failures in the monotherapy arm reached 5%. The Board considered that the rate of viral failure in the dolutegravir monotherapy arm exceeded the safety threshold stated in the protocol and was clinically relevant because it was associated with resistance mutations. The Board recommended the immediate interruption of the dolutegravir monotherapy arm of the DOLAM Study. In contrast, the occurrence of one viral failure not associated with resistance mutations in the dolutegravir/lamivudine dual-therapy arm was not deemed by the DSMB as sufficiently relevant to recommend the interruption of this study arm. These decisions were unanimously taken in a written report by the three members of the DOLAM Study DSMB. Following the DSMB report, the investigators of the DOLAM Study decided to stop the dolutegravir monotherapy arm, and to amend the protocol to continue with the control and dual-therapy arms only until completion of the study. Patients assigned to the dolutegravir monotherapy arm were advised on the higher risk of viral failure and the potential development of resistance mutations. They were strongly recommended to switch their therapy to a safer regimen but the final decision depended on each patient's wishes.
Discussion
To our knowledge, DOLAM is the only study that has directly compared dolutegravir/lamivudine dual therapy versus dolutegravir monotherapy as potential dolutegravir-based simplification strategies in a face-to-face randomized clinical trial. In the phase A of the DOLAM Study reported here, we found that the incidence of viral failures in the dolutegravir monotherapy arm exceeded the protocol pre-established threshold of 5% at 24 weeks. Viral failures in patients under dolutegravir monotherapy did not occur early but at the end of the 24 week period. In addition, the two patients experiencing viral failure under dolutegravir monotherapy developed de novo mutations, suggesting cross-resistance to all currently licensed integrase inhibitors. Two dolutegravir-based less-drug maintenance regimens
JAC
In both patients, multiple mutations were developed in the presence of low-level viraemia and despite adequate dolutegravir plasma levels and adherence to therapy. These results are in accordance with those of a recently published randomized clinical trial comparing maintenance dolutegravir monotherapy with combination ART. 14 In that trial, eight (8%) patients treated with dolutegravir monotherapy experienced viral failure and three of them showed one resistance mutation each (S230R, R263K and N155H) despite adequate plasma dolutegravir levels and self-reported adherence. In addition, a recent systematic review and meta-analysis of dolutegravir-based simplified therapy in HIV-infected patients 15 that provided precise estimates of viral failure rate on dolutegravir-based mono-and dual-therapy maintenance (including not only dolutegravir/lamivudine, but also dolutegravir/rilpivirine) showed that the rate of viral failure was 10-fold higher for dolutegravir monotherapy (3.18%) than for dolutegravir-based dual therapy (0.32%) at 24 weeks, but the difference increased further to 20-fold higher at 48 weeks (8.91% versus 0.41%), suggesting that the risk of viral failure and development of resistance mutations with dolutegravir monotherapy may be higher after the first 24 weeks. All together, these data suggest that dolutegravir used as monotherapy is not potent enough and/or its genetic barrier to resistance is insufficient to prevent development of resistance despite optimal adherence, and therefore this strategy should not be used.
In summary, in the planned 24 week analysis of two dolutegravir-based simplification strategies (DOLAM Study), the dolutegravir monotherapy arm showed an unacceptable risk of viral failure with development of integrase inhibitor crossresistance mutations and this arm was stopped and not further recommended, whereas the dolutegravir ! lamivudine dual-therapy arm showed no warning signs. Based on the phase A results, the DOLAM Study protocol has been amended to two arms only (dolutegravir/lamivudine dual therapy versus control), the sample size has been recalculated and additional centres have been invited to complete phase B of the study. Two dolutegravir-based less-drug maintenance regimens JAC
